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Atrial fibrillation is associated with multiple adverse outcomes including embolic stroke, 2 cognitive impairment, 3 heart failure, 4 myocardial infarction, 5 chronic kidney disease, 6 and mortality. 2, 7 Over the past few decades, several studies have defined major risk factors for AF including body mass index, hypertension, diabetes mellitus, history of cardiovascular disease, genetic factors, and various circulating biomarkers. [7] [8] [9] [10] [11] Brain-derived neurotrophic factor (BDNF) is a growth factor with roles within the nervous system 12 and cardiovascular system. 13 It is expressed in endothelial cells, and its release is modified by stimuli including laminar shear stress and changes in intracellular calcium. 13, 14 Furthermore, decreased BDNF levels reduce endothelial cell survival and reduce cardiac contractility, whereas activation of tyrosine receptor kinase B by BDNF is associated with angiogenesis. 13 It is unclear if these effects of BDNF on the cardiovascular system may modify the risk of AF. However, lower BDNF concentrations have been associated with known risk factors for AF including advancing age, 15, 16 male sex, 16 alcohol consumption, 17 smoking, 18 and diabetes mellitus ( Figure) . 19 Circulating BDNF levels were higher among individuals with higher mean physical activity, 20 diastolic blood pressure, and body mass index. 16 In contrast, lower serum BDNF levels have been associated with adverse outcomes, including cardiovascular events 21 and dementia. 22 Brain-derived neurotrophic factor may have a role in the development of acute coronary syndrome, which may be partly through modulation of associated inflammatory pathways. [23] [24] [25] Because of BDNF's association with multiple AF risk factors, inflammatory pathways, and its role in the cardiovascular system, we hypothesized that lower BDNF concentrations are associated with increased risk of developing AF prospectively. Thus, we sought to determine if serum BDNF concentrations are associated with 10-year incidence of AF in the community.
Methods

Study sample
The Framingham Heart Study (FHS) is a longitudinal, community-based, epidemiologic cohort study. Details of the FHS original and offspring cohorts have been described previously. 26, 27 From 1948 through 1953, 5,209 participants were enrolled into the original cohort. In addition, 5,124 children of the original cohort and their spouses were recruited into the offspring cohort between 1971 and 1975. Participants have undergone routine follow-up examinations biennially for the original cohort and every 4 to 8 years for the offspring cohort. Six hundred sixty-nine of the 1,026 participants from the original cohort who attended examination 23 (1992-1996) , and 3,020 of 3,539 participants from the offspring cohort who attended examination 7 (1998-2001) had circulating BDNF measurements. We excluded participants with prevalent AF (n = 214) and those younger than 40 years (n = 18) at BDNF measurements (baseline), resulting in a sample of 3,457 for our study. All participants gave informed consent. The study protocol was approved by the institutional review board of Boston University Medical Center.
Clinical variables
Participants' medical history, physical examination, blood tests, and 12-lead electrocardiogram were obtained routinely at each FHS examination. In addition, records including electrocardiograms from outpatient visits or hospitalizations between examinations were routinely retrieved and reviewed. Participants were defined to have AF if AF or atrial flutter was confirmed by an FHS cardiologist on review of electrocardiograms, as detailed previously. 27 We included clinical covariates from the FHS AF risk score 28 assessed at baseline by standardized protocols. Body mass index (weight [in kilograms] divided by height [in meters] squared) was calculated. The PR interval was measured from the beginning of the P-wave deflection to the end of the PR segment at the junction with the QRS complex. Body mass index and PR interval were natural log transformed to normalize the skewed distributions. Systolic blood pressure and self-reported use of antihypertensive and diabetes medications were recorded. Diabetes mellitus was diagnosed if the participant used insulin or oral hypoglycemic agents, had fasting glucose level ≥126 mg/dL, or had random blood glucose level ≥200 mg/dL at FHS examination. We defined valvular heart disease as ≥grade 3/6 systolic murmur or any diastolic murmur auscultated at FHS examination. Myocardial infarction and heart failure were diagnosed by review of hospital records and physician reports, and adjudicated by 3 FHS investigators. 29 
Laboratory measurements of BDNF
Fasting blood tests were obtained, frozen, and stored at −70°C until assayed. Serum BDNF concentrations were measured using enzyme-linked immunosorbent assay kits (R&D Systems, Minneapolis, MN). The intra-assay and interassay coefficients of variation for BDNF were 4.8% and 7.6%, respectively.
Statistical analyses
We followed up participants for 10 years to evaluate for risk of incident AF. We used unadjusted, age-and sex-adjusted, and multivariable-adjusted Cox proportional hazards regression models to examine the association of change in serum BDNF concentrations (per SD) with 10-year risk of incident AF. Multivariable models were adjusted for age, sex, FHS cohort (original vs offspring), body mass index, PR interval, systolic blood pressure, hypertension treatment, diabetes mellitus, significant heart murmur, history of myocardial infarction, and history of heart failure. Estimates were adjusted for competing risk of death. In addition, in exploratory analyses, we adjusted for each individual covariate separately to understand if any potential relationship existed between a specific risk factor, serum BDNF concentrations, and risk of incident AF.
In secondary analyses, we considered nonlinear associations and divided participants into quartiles using serum BDNF concentrations. In previous studies, lower concentrations of BDNF were associated with higher risk of dementia. 22 Thus, the lowest quartile, Q1, was used as the reference to compare with each individual quartile and a combined Q2 to Q4. Subsequently, the highest quartile (Q4) was used as reference and compared with the other quartiles pooled. The same analyses were performed on all models after exclusion of participants with history of myocardial infarction or heart failure. We also evaluated if there was an interaction of sex and age b65 or ≥65 years with BDNF for the risk of AF.
Analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC), and 2-sided P b .05 was considered statistically significant for all models and P b .10 for analyses assessing interactions. We estimate that our study had 90% power to detect a hazard ratio (HR) as large as 0.86 for AF incidence with 1-SD change of BDNF.
Results
Of the 3,457 participants included in the study, the mean age was 64.5 ± 11.3 years and 58% were women. Table I shows the baseline characteristics of the study participants.
During up to 10 years of follow-up, 395 individuals developed AF. Table II shows the association of serum BDNF concentrations and risk of incident AF. In unadjusted analysis, higher mean serum BDNF concentration was associated with lower incidence of AF (HR per SD change 0.89, 95% CI 0.80-0.99, P = .02). In exploratory analyses, after adjustment for age or sex, there was no statistically significant association of serum BDNF concentrations and risk of incident AF (Supplementary Table I ).
In secondary analysis examining for nonlinear associations, in unadjusted analyses, a statistically significant lower risk of incident AF was noted with higher BDNF quartiles. However, we did not observe any statistically significant difference among BDNF quartiles in the risk of incident AF in age-and sex-adjusted or multivariable-adjusted analyses. Comparing Q1 with pooled Q2 to Q4, there was a borderline statistically significant association with AF incidence in unadjusted analysis, but no statistically significant association was observed after multivariable adjustment (Table II) . Compared with the fourth quartile, the risk of incident AF in the other 3 quartiles did not differ, either (Supplementary Table 2 ).
There was no significant interaction of sex (P = .86) or age (b65 vs ≥65 years; P = .45) with BDNF levels and risk of AF. If participants with history of myocardial infarction or heart failure were excluded (n = 179), there continued to be no statistically significant association of 
Discussion
Our study evaluated if serum BDNF concentrations were associated with 10-year risk of incident AF in the FHS. Although in unadjusted analyses, higher mean serum BDNF concentrations were associated with lower risk of incident AF, after adjustment for age or sex, no persistent association was found. As noted above in Figure, serum BDNF concentrations were lower with higher mean age and were lower in men compared with women. 15, 16 Brain-derived neurotrophic factor is expressed by endothelial cells, 13 and lower serum BDNF levels are associated with higher risk of cardiovascular events. 21 Brain-derived neurotrophic factor modulates cadherin expression and shedding 30, 31 and interacts with tumor necrosis factor α. 32, 33 Both cadherin 34 and tumor necrosis α [35] [36] [37] contribute to atrial structural remodeling in human and animal studies, and therefore, changes in BDNF may promote development of a substrate vulnerable to AF. We hypothesized that BDNF is associated with incident AF, possibly through modulation of endothelial cells. However, our findings in a prospective, community-based Table I . Baseline characteristics of the study sample cohort did not support our hypothesis. Furthermore, we failed to find a threshold effect, or interactions with sex or age. Our study has several strengths including the availability of long-term follow-up, comprehensive evaluation of clinical covariates and adjudication of cardiovascular outcomes, and consistent FHS adjudication of electrocardiograms for AF by a cardiologist. However, there are several limitations. The generalizability of the study is potentially limited by the largely white, middle-aged, and older adults included in the FHS, and therefore, our findings may not be translated to younger individuals or other races/ethnicities. Furthermore, we measured BDNF concentration at a single point, and it is possible that the longitudinal trend in BDNF concentrations or levels at an earlier age is more important (mean age in our study was 65 ± 11 years). Single-point BDNF measurements may be affected by recent patient factors, for example, exercise, diet, or time of measurement. In addition, we examined circulating BDNF and cannot comment on the relation of left atrial tissue BDNF and risk of AF. Atrial fibrillation in the population is known to be underdiagnosed, which may be the case in the FHS leading to possible misclassification bias. 38 Our follow-up period was 10 years, but a longer duration of follow-up may provide different findings. We did not distinguish between AF and atrial flutter and between AF types; we cannot exclude variation in the relation between BDNF and subtypes of AF.
Conclusion
In our moderate-sized, community-based sample, serum BDNF concentrations were not associated with 10-year risk of incident AF. Given BDNF's role as a growth factor, future studies may investigate if tissue levels of BDNF or circulating BDNF levels during early adulthood, or serial BDNF concentrations influence AF risk.
Disclosures
Dr Ellinor is the principal investigator on a grant from Bayer HealthCare to the Broad Institute focused on the genetics and therapeutics of AF.
Figure
The factors and outcomes associated with BDNF. Brain-derived neurotrophic factor is released in the nervous system and by endothelial cells. Several factors can increase or decrease BDNF levels. Serum BDNF levels have been demonstrated to be associated with dementia and cardiovascular events. The gray boxes include continuous variables in which increases in the risk factors are associated with changes in BDNF levels.
